controls were a mean of 75 years old and the ADNI
Alzheimer's patients, 76.
model of AD progression described suggests when biomarkers and imaging techniques are likely to be most useful in diagnosis, tracking disease progression, and assessing effectiveness of treatments.
For more information regarding multisite studies, see the ADNI
The investigators used observational data from ADNI
to show that, out of 675 measurements made at time points of 0, 6, 12, and 24 months, data from ADAS-Cog total scores spanned the entire range of the scale and had no floor or ceiling effects that would reduce its ability to measure changes and differences in lower-functioning or higher-functioning patients, respectively However, 8 of the scale's 11 components (all except for word recall, word recognition, and orientation) had statistically significant ceiling effects with a skewed distribution of scores (Alzheimers Dement.
Because often greater than three-fourths of the participants with mild Alzheirner's disease in the ADNI
study scored either 0 or 1 on the majority of ADAS-Cog components, Dr.
is a research partnership supported primarily by the National Institute on Aging (NIA), part of the National Institutes of Health, with private sector support through the Foundation for NIH, seeking to find neuroimaging and biomarker tests that can detect Alzheimer's disease progression and measure the effectiveness of potential therapies.
is a global effort to improve ways of identifying the best patients for clinical trials, using brain imaging and other biomarkers.
Launched in 2004, the ADNI
studied the rate of change of cognition, brain structure and function, and biomarkers in healthy control patients, patients with mild cognitive impairment, and patients with Alzheimer's disease.
The third was the largest database, and it had 219 PET images provided by ADNI
Patients participating in the ADNI
and other trials have been far more accepting of LP, even repetitive LP, than anticipated.
Analyses based on the mild patients from the ADNI
study had similar limitations of small sample size but again replicated the findings that cognitive impairment predicted future functional impairment.
substudy was sponsored by the Litwin-Zucker Alzheimer's Center and the Instituto de Salud Carlos III.